Last reviewed · How we verify

Intravenous Lipid Emulsion

Stanley Dudrick's Memorial Hospital · FDA-approved active Small molecule Quality 5/100

Intravenous Lipid Emulsion is a Small molecule drug developed by Stanley Dudrick's Memorial Hospital. It is currently FDA-approved. Also known as: Intralipid, ATC: B05BA02.

At a glance

Generic nameIntravenous Lipid Emulsion
Also known asIntralipid, ATC: B05BA02
SponsorStanley Dudrick's Memorial Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intravenous Lipid Emulsion

What is Intravenous Lipid Emulsion?

Intravenous Lipid Emulsion is a Small molecule drug developed by Stanley Dudrick's Memorial Hospital.

Who makes Intravenous Lipid Emulsion?

Intravenous Lipid Emulsion is developed and marketed by Stanley Dudrick's Memorial Hospital (see full Stanley Dudrick's Memorial Hospital pipeline at /company/stanley-dudrick-s-memorial-hospital).

Is Intravenous Lipid Emulsion also known as anything else?

Intravenous Lipid Emulsion is also known as Intralipid, ATC: B05BA02.

What development phase is Intravenous Lipid Emulsion in?

Intravenous Lipid Emulsion is FDA-approved (marketed).

Related